B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target

Benzinga · 03/16/2023 10:52
B of A Securities analyst Koichi Mamegano upgrades Takeda Pharmaceutical (NYSE:TAK) from Neutral to Buy and announces $20 price target.
Recently
Symbol
Price
%Change